Physiology first and target identification later

In many disease contexts ––including cardiomyopathies, skeletal myopathies, vasospasm, bronchospasm, and cancer cell invasion–– cellular contractile force is a logical therapeutic target. To correctly hit that pathophysiological target, new drugs are often sought by means of unbiased high-throughput drug screens that focus upon molecular proxies for contractile force but are blind to contractile force itself. To overcome that limitation, and thus accelerate drug discovery, we present, Contractile Force Screening (CFS).

Drug screening using CFS


Human airway smooth muscle (ASM) cells were cultured to confluence upon Young’s modulus = 12 kPa (0.36% cross-linker) collagen-coated 96-well silicone substrates. (A–D) For a representative well of a 96-well plate, images of cells, fluorescent beads, traction force maps, and average magnitude (inset) at baseline are shown. (E and F) For the same well, shown are contraction maps and the average magnitude (inset) with the contractant compound histamine (10 μM, 30 min), and after additional treatment with the relaxant compound isoproterenol (0.5 μM, 30 min). (G) Over the 96-well plate, the force measurements are statistically different (p < 0.05) between positive and negative controls, as ascertained by an unpaired t-test. (H) Force measurements confirmed known differences in potency among a panel of functionally diverse ASM relaxation compounds (formoterol > salmeterol > salbutamol > isoproterenol). Plotted are the mean ± standard error calculated from three to eight wells per dose per ASM relaxation compound. Data were pooled from two to four 96-well plates tested on different days but under identical experimental conditions.
Yoshie et al, Biophys J . 2018 May 8;114(9):2194-2199.


The CFS Advantage

   1) It interrogates simultaneously the entire,
vast diversity of cellular physiological targets
 
2)  It is human cell based and focused on
well-established biomechanical endpoints
in the heart, lung, bladder, and vasculature

3) It is label-free, non-invasive, and uses
physiological stiffness substrates

4) It overcomes the poor predictive ability
of canonical high-throughput screening
assays that target cell contraction

Statistics

Small

Set-up Cost

<1 week

Set-up time

Fast

Up to 1000 compounds per screening day

Let Us Run Your Experiments

CRO Services

Bespoke modeling and drug testing for PAH, asthma, COPD, and drug toxicity. 

Disease-derived or disease-induced conditions

Active partnerships with industry leaders

Please contact us for more details